Jasper Seeks Approval to Convert 604M Preferred Shares — 95% Dilution for Existing Holders
JSPR sits 81% above its 52-week low of $0.315 on light trading volume (0.2× avg).
Summary
Jasper's preliminary proxy seeks stockholder approval to convert 9.9M preferred shares into 604.3M common shares — a 95% dilution that would hand ~93% ownership to Kira equityholders and PIPE investors. Nasdaq listing application approval is also required before the November vote.
Key Events · Corporate Governance and Compliance · JSPR
-
604M Share Conversion Vote
Stockholders asked to approve conversion of 9,906,591 preferred shares into 604,302,051 common shares — approximately 95% of the 33.3M shares currently outstanding on an as-converted basis.
-
Ownership Shift to Kira and PIPE Investors
Post-conversion, pre-transaction Jasper holders would own ~6.68%, former Kira equityholders ~49.86%, and PIPE investors ~43.46% — a near-total change of control.
-
PIPE Priced Below Nasdaq Minimum
The $132M PIPE implies a conversion price of ~$0.4648 per share, below Nasdaq's Minimum Price, triggering Rule 5635(d) stockholder approval.
-
Nasdaq Listing Application Required
Nasdaq must conditionally approve a new listing application before the November special meeting; failure to obtain approval risks delisting, compounding existing bid price and stockholders' equity deficiencies.
Analysis · JSPR · Life Sciences
This preliminary proxy quantifies the massive dilution embedded in the July Kira merger and $132M PIPE. If approved, 9.9M preferred shares convert into 604.3M common shares — roughly 95% of the current outstanding count on an as-converted basis. Existing Jasper holders would be cut to about 6.68% ownership, while former Kira equityholders and PIPE investors would control ~93%. The filing also reveals the PIPE conversion price of ~$0.4648 is below Nasdaq's Minimum Price, triggering Rule 5635(d) approval, and that Nasdaq must conditionally approve a new listing application before the November special meeting — failure to do so risks delisting. Against the backdrop of two Nasdaq deficiency notices (minimum bid price and stockholders' equity) and a going-concern warning, this vote is effectively a referendum on whether the company can complete its reverse-merger recapitalization and remain listed.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.32 to $2.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.